Company intelligence / Profile preview
Transgene SA
Illkirch-Graffenstaden, Alsace, Francetransgene.fr ↗
- Ownership
- Public · TNG
- Employees
- ~162
- Development stage
- Phase 2
01
Overview
TG4050 has shown clinical proof of principle in head and neck cancer as presented at SITC 2024. The company recently announced updated Phase I data for TG4050 to be presented at ASCO 2025.
- Therapeutic areas
- Oncology
- Modalities
- Therapeutic vaccinesoncolytic virusesimmunotherapeutics
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
03
Partnerships
NEC (artificial intelligence for myvac®)BioInvent (ICI vectorization)Alliance of Merck KGaA and Pfizer (TG4001)MSD (BT-001)
04
Financials
- Market cap
- $229.2M
- Total revenue
- $547.5K
- Enterprise value
- $127.8M
Beyond the preview
Go deeper on Transgene SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transgene SA.